KLOW Blend

Profile · 01

Overview

KLOW is a four-peptide regenerative blend combining TB-500, BPC-157, KPV, and GHK-Cu, designed to provide broad-spectrum tissue repair, anti-inflammatory, and connective tissue support through complementary mechanisms. None of the individual components are FDA-approved for therapeutic use. Preclinical models support accelerated wound healing, collagen synthesis, and inflammation modulation for each component, though human clinical data remain limited to early-phase studies of individual peptides. This protocol presents a gradual titration subcutaneous approach using practical dilution for clear insulin-syringe measurements.

At a Glance

Goal

Support tissue repair, reduce inflammation, enhance connective tissue healing and recovery

Protocol

Suggested daily titration approach starting low and increasing every two weeks with a maintenance phase.

Typical daily range

2,000–6,000 mcg total blend once daily (gradual titration)

Start

~2,000 mcg daily (7.5 units); increase every 2 weeks as tolerated

Target

~6,000 mcg daily by Weeks 5–8; maintenance at ~4,000 mcg Weeks 9–12

Frequency

Once per day (subcutaneous)

Cycle Length

8–12 weeks; optional extension to 16 weeks

Timing

Any consistent time; rotate injection sites

Route

Subcutaneous

Cycle

8–12 weeks on, 4 weeks off

Inject once daily subcutaneously using the largest practical dilution to maintain measurement accuracy. The four-peptide blend provides broader regenerative coverage than single-peptide protocols. Dosing extrapolates from preclinical models of individual components; human clinical validation for this specific combination remains unavailable.

Dose progression

Weeks 1–2

2,000 mcg (TB-500: 250 mcg, BPC-157: 250 mcg, KPV: 250 mcg, GHK-Cu: 1,250 mcg)

Weeks 3–4

4,000 mcg (TB-500: 500 mcg, BPC-157: 500 mcg, KPV: 500 mcg, GHK-Cu: 2,500 mcg)

Weeks 5–8

6,000 mcg (TB-500: 750 mcg, BPC-157: 750 mcg, KPV: 750 mcg, GHK-Cu: 3,750 mcg)

Weeks 9–12

4,000 mcg maintenance (TB-500: 500 mcg, BPC-157: 500 mcg, KPV: 500 mcg, GHK-Cu: 2,500 mcg)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Profile · 03

Videos

Science · 01

How KLOW Blend works.

KLOW combines four peptides with distinct but complementary mechanisms. TB-500 (Thymosin Beta-4) promotes angiogenesis, cell migration, and tissue repair by regulating actin, a key protein in cell structure; preclinical studies demonstrate accelerated wound healing, reduced inflammation, and tissue regeneration. BPC-157 is a gastric pentadecapeptide that supports tendon, ligament, and muscle healing through enhanced angiogenesis and growth factor modulation; animal studies show favorable tissue repair outcomes. KPV is a C-terminal tripeptide fragment of alpha-MSH with potent anti-inflammatory properties that inhibits NF-kB signaling and reduces pro-inflammatory cytokines. GHK-Cu is a naturally occurring copper peptide that stimulates collagen and elastin synthesis, promotes wound healing, and modulates gene expression related to tissue remodeling. Together, these four peptides address tissue repair, inflammation, collagen synthesis, and immune modulation through synergistic pathways.

Science · 02

Effects

Observations from clinical or preclinical literature.

Accelerated tissue repair and wound healing through complementary regenerative pathways (animal data)

Reduced inflammation via NF-kB inhibition (KPV, GHK-Cu) and cytokine modulation (TB-500, BPC-157)

Enhanced collagen synthesis and connective tissue support (GHK-Cu, BPC-157)

Promotion of angiogenesis and improved blood flow to healing tissues (TB-500, BPC-157)

Potential support for musculoskeletal recovery and joint health (preclinical, under investigation)

Mild injection-site reactions (redness, irritation) may occur with subcutaneous administration

Occasional lightheadedness reported with some peptides due to vasodilatory effects

Limited human clinical data; most safety observations derive from preclinical studies

Science · 03

Caution

Individuals with active cancer or a history of cancer should avoid use due to pro-angiogenic properties of TB-500 and BPC-157

Not recommended during pregnancy or breastfeeding (no safety data available)

Use with caution if taking anticoagulants or medications affecting blood clotting

Individuals with copper metabolism disorders (e.g., Wilson's disease) should avoid GHK-Cu-containing blends

Consult a healthcare provider before use if you have any chronic medical conditions

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Vitamin C

Essential cofactor for collagen synthesis; supports the regenerative actions of GHK-Cu and BPC-157.

Zinc

Supports wound healing and immune function; commonly depleted in tissue injury.

Copper

Critical for GHK-Cu function and collagen cross-linking; ensure adequate but not excessive intake.

Magnesium

Supports enzymatic processes involved in tissue recovery.

Omega-3 fatty acids

Support anti-inflammatory pathways complementary to KPV and BPC-157 mechanisms.

Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Pair with balanced, protein-forward diet supporting tissue repair and recovery

Combine resistance training and mobility work to reinforce musculoskeletal adaptations

Prioritize sleep (7–9 hours) and stress management to optimize natural regenerative processes

Stay well-hydrated to support peptide absorption and metabolic function

Ensure adequate micronutrient intake, particularly vitamin C, zinc, and copper

Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

Pain levels and functional mobility — monitor changes in target areas to gauge healing response
Inflammation markers (subjective swelling, redness, heat) — track daily to identify trends
Skin quality and wound healing progress — monitor changes in texture, elasticity, and healing rate
Sleep quality and recovery perception — poor sleep impairs healing; track to ensure adequate rest
Injection-site reactions — note any redness, swelling, or discomfort to guide site rotation

Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

CRP (C-Reactive Protein)

General inflammation marker; track before and during protocol.

CBC (Complete Blood Count)

Monitor overall health and rule out underlying conditions.

CMP (Comprehensive Metabolic Panel)

Assess liver and kidney function during peptide use.

Copper and Ceruloplasmin levels

Monitor copper status given GHK-Cu component.

ESR (Erythrocyte Sedimentation Rate)

Secondary inflammation marker to corroborate CRP trends.

Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length

Vial size

Bac. water

Syringe

Vials

0 × 80 mg each…

Syringes

Bac. water

0 mL

Swabs

02 per syringe

Calculators · 02

Dose Calculator

Vial

Bac. water

Syringe

Dose

Concentration

0mcg/mL

Volume per dose

0mL

…

Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

Allow vial to reach room temperature for 15–20 minutes before reconstitution.
Draw the chosen bacteriostatic water volume with a sterile syringe.
Inject slowly down vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Use within 30 days; discard any unused solution after 30 days.

Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and skin with alcohol; allow to dry

Pinch a skinfold; insert needle at 45–90° into subcutaneous tissue

Do not aspirate for subcutaneous injections; inject slowly and steadily

Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy

Apply gentle pressure after withdrawal; do not massage injection site

Discard used syringes immediately in sharps container per WHO guidelines

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized

Store at room temp in dry, dark conditions; minimize moisture exposure.

Reconstituted

Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.

Reference · 01

Notes

Use new sterile insulin syringes for each injection; dispose in sharps container

Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation

Inject slowly; wait a few seconds before withdrawing the needle

Document daily dose and site rotation to maintain consistency

This multi-peptide blend may provide broader regenerative support than single-peptide protocols; human data for this combination are unavailable

Reference · 02

References

Current Pharmaceutical Design (PMC)
Sikiric P et al., "BPC-157 stable gastric pentadecapeptide: novel therapy for wound healing and tissue repair".
https://pmc.ncbi.nlm.nih.gov/articles/PMC5333585/
HSS Journal/PMC (2025)
Vasireddi N et al., "Emerging use of BPC-157 in orthopaedic sports medicine: systematic review".
https://pmc.ncbi.nlm.nih.gov/
Expert Opinion on Biological Therapy/PubMed (2012)
Crockford D, "Thymosin Beta-4: properties and applications in tissue repair".
https://pubmed.ncbi.nlm.nih.gov/
Molecular Therapy Methods & Clinical Development/PMC (2017)
Dalmasso G et al., "KPV tripeptide for inflammatory bowel disease".
https://pmc.ncbi.nlm.nih.gov/
International Journal of Molecular Sciences (2018)
Pickart L et al., "GHK-Cu regenerative and protective actions relevant to skin and connective tissue".
https://www.mdpi.com/1422-0067/19/7/1987
Frontiers in Endocrinology (2021)
"Thymosin Beta-4 function and application in tissue repair".
https://www.frontiersin.org/journals/endocrinology
CDC Pink Book, 14th Edition (2022)
"Vaccine administration: subcutaneous route guidelines".
https://www.cdc.gov/vaccines/pubs/pinkbook/
WHO (NCBI Bookshelf)
"Guideline on safety-engineered syringes for IM, ID, and SC injections in health care settings (2016)".
https://www.ncbi.nlm.nih.gov/books/NBK390474/
Subcutaneous Drug Injection Review (PMC)
"Pharmacologic considerations of the subcutaneous route".
https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/